These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 29299769)

  • 1. The Direct Medical Costs of Diseases Associated with Human Papillomavirus Infection in Manitoba, Canada.
    Righolt CH; Pabla G; Mahmud SM
    Appl Health Econ Health Policy; 2018 Apr; 16(2):195-205. PubMed ID: 29299769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost of Preventing, Managing, and Treating Human Papillomavirus (HPV)-Related Diseases in Sweden before the Introduction of Quadrivalent HPV Vaccination.
    Östensson E; Fröberg M; Leval A; Hellström AC; Bäcklund M; Zethraeus N; Andersson S
    PLoS One; 2015; 10(9):e0139062. PubMed ID: 26398189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic burden associated with the management of cervical cancer, cervical dysplasia and genital warts in Belgium.
    Annemans L; Rémy V; Lamure E; Spaepen E; Lamotte M; Muchada JP; Largeron N
    J Med Econ; 2008; 11(1):135-50. PubMed ID: 19450115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost analysis of Human Papillomavirus-related cervical diseases and genital warts in Swaziland.
    Ginindza TG; Sartorius B; Dlamini X; Östensson E
    PLoS One; 2017; 12(5):e0177762. PubMed ID: 28531205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK.
    Brown RE; Breugelmans JG; Theodoratou D; Bénard S
    Curr Med Res Opin; 2006 Apr; 22(4):663-70. PubMed ID: 16684427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature.
    Insinga RP; Dasbach EJ; Elbasha EH
    Pharmacoeconomics; 2005; 23(11):1107-22. PubMed ID: 16277547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health and economic burden of HPV-related diseases in Singapore.
    Low JJ; Ko Y; Ilancheran A; Zhang XH; Singhal PK; Tay SK
    Asian Pac J Cancer Prev; 2012; 13(1):305-8. PubMed ID: 22502690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic burden of human papillomavirus-related diseases in Italy.
    Baio G; Capone A; Marcellusi A; Mennini FS; Favato G
    PLoS One; 2012; 7(11):e49699. PubMed ID: 23185412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The healthcare costs of treating human papillomavirus-related cancers in Norway.
    Hylin H; Thrane H; Pedersen K; Kristiansen IS; Burger EA
    BMC Cancer; 2019 May; 19(1):426. PubMed ID: 31064346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medical Care Costs Associated with Genital Warts for Commercially Insured US Patients.
    Dahlstrom KR; Fu S; Chan W; Shelal Z; Ramondetta LM; Lairson DR
    Pharmacoeconomics; 2018 Nov; 36(11):1355-1365. PubMed ID: 30019118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resource Use and Cost of Treating Human Papillomavirus-Related Lesions in Japanese Women.
    Mizukami A; Kaise T; Van Kriekinge G
    Value Health Reg Issues; 2018 May; 15():56-62. PubMed ID: 29474179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
    Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
    Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The economic burden of human papillomavirus infection-associated diseases in the Republic of Korea, 2002-2015.
    Ki M; Choi HY; Han M; Oh JK
    Vaccine; 2018 Jul; 36(31):4633-4640. PubMed ID: 29961603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
    Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
    Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study.
    Brisson M; Laprise JF; Drolet M; Van de Velde N; Franco EL; Kliewer EV; Ogilvie G; Deeks SL; Boily MC
    Vaccine; 2013 Aug; 31(37):3863-71. PubMed ID: 23830974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
    Gomez JA; Lepetic A; Demarteau N
    BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States.
    Chesson HW; Ekwueme DU; Saraiya M; Watson M; Lowy DR; Markowitz LE
    Vaccine; 2012 Sep; 30(42):6016-9. PubMed ID: 22867718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada.
    Brisson M; Van de Velde N; De Wals P; Boily MC
    Vaccine; 2007 Jul; 25(29):5399-408. PubMed ID: 17561316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The economic burden of human papillomavirus-related precancers and cancers in Sweden.
    Östensson E; Silfverschiöld M; Greiff L; Asciutto C; Wennerberg J; Lydrup ML; Håkansson U; Sparén P; Borgfeldt C
    PLoS One; 2017; 12(6):e0179520. PubMed ID: 28651012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Updated estimate of the annual direct medical cost of screening and treatment for human papillomavirus associated disease in the United States.
    Clay PA; Thompson TD; Markowitz LE; Ekwueme DU; Saraiya M; Chesson HW
    Vaccine; 2023 Mar; 41(14):2376-2381. PubMed ID: 36907737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.